$TRIB

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

Trinity Biotech plc (Nasdaq: TRIB) reported clinical results for its CGM+ multi-sensor wearable, analyzing ~5,000 hours of device wear data from insulin-dependent people with diabetes in a pre-pivotal trial completed in Q2 2026. The company says an algorithm distinguishes nocturnal compression-related false low glucose alarms from true lows, addressing a limitation of glucose-only CGMs.

Trinity Biotech plc (Nasdaq: TRIB) said it notified YA II PN, LTD., an affiliate of Yorkville Advisors Global, that it is terminating its Standby Equity Purchase Agreement (SEPA) equity line of credit. The company stated it will not use the SEPA further and cited its current financing strategy.

Trinity Biotech (NASDAQ: TRIB) launched Trinovium, a new subsidiary targeting advanced liquid cooling fluids and “fluid intelligence” systems for AI data centers and high-performance computing. The company said it will use existing US/EU manufacturing capacity and its high-purity fluid and analytical technologies. Trinity cited MarketsandMarkets projecting the liquid cooling market rising from $4B (2026) to $27B (2033).

Trinity Biotech (TRIB) updated on Q4 2025 trading and business progress, projecting Q4 2025 revenue of $11.5M–$12.5M, a decrease from Q4 2024 due to HIV testing market disruptions and manufacturing transitions. Despite this, the company highlighted positive developments such as regulatory approval to outsource Uni-Gold manufacturing, growing demand for its rapid HIV tests, IFCC Gold classification for its HbA1c solution, and ongoing development of new products like CGM+, EpiCapture, and PrePsia. The market reacted positively, with TRIB stock gaining 5.10% following the news, reflecting investor confidence in the company's long-term transformation strategy.

This article details the stocks making significant moves in Tuesday's midday trading. Novo Nordisk (NVO) is up after FDA approval for its Wegovy pill, Trinity Biotech (TRIB) rose on a large order for its HIV diagnostic test, and VisionWave (VWAV) increased due to a new patent. Conversely, Starfighters Space (FJET) experienced a drop after a massive rally, and ServiceNow (NOW) fell following its acquisition of a cybersecurity startup.

DUBLIN, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc ( NASDAQ:TRIB ) , a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has received World Health Organization ( WHO ) approval for ...

Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, EBITDA Accretion and Cashflow Generation Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, EBITDA Accretion and Cashflow Generation ...

DUBLIN, Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc ( Nasdaq: TRIB ) , a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with a leading bioinformatics ...

DUBLIN, Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc ( NASDAQ:TRIB ) , a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with a leading bioinformatics ...